Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired sensory-motor neuropathy with autoimmune pathogenesis. First line treatments include corticosteroids, plasmapheresis, and immunoglobulin therapy. The classic form of immunoglobulin administration is intravenous, however subcutaneous immunoglobulin (SCIG) therapy became a valid alternative option especially for maintenance therapy. Cross-sectional study to compare long-term response to intravenous immunoglobulin (IVIG) and SCIG.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
